Abciximab therapy is associated with increased platelet activation and decreased heparin dosage in patients with acute myocardial infarction

Thrombosis and Haemostasis

Volumn 94, Issue 2, 2005, Pages 422-426

  Piorkowski, Michael ^a   Priess, Jana ^a   Weikert, Ulf ^a   Jaster, Markus ^a   Schwimmbeck, Peter Lothar ^a   Schultheiss, Heinz Peter ^a   Rauch, Ursula ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Abciximab; Heparin; Platelet activation

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; PADGEM PROTEIN; THROMBOPLASTIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING PARAMETERS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; PARTIAL THROMBOPLASTIN TIME; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; THROMBOCYTE ACTIVATION;

AGED; ANTIBODIES, MONOCLONAL; BLOOD PLATELETS; BODY MASS INDEX; FEMALE; FLOW CYTOMETRY; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFLAMMATION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PARTIAL THROMBOPLASTIN TIME; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RISK; RISK FACTORS; TIME FACTORS;

EID: 23744466831     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH04-12-0835     Document Type: Article

References (28)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330: 956-61.
2. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87-92.
3. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997; 336: 1689-96.
4. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. The GUSTO IV-ACS Investigators. Lancet 2001; 357: 1905-14.
5. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998; 338: 1488-97.
6. Peter K, Schwarz M, Ylanne J et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 1998; 92: 3240-9.
7. Schneider DJ, Taatjes DJ, Sobel BE. Paradoxical inhibition of fibrinogen binding and potentiation of alpha-granule release by specific types of inhibitors of glycoprotein IIb-IIIa. Cardiovasc Res 2000; 45: 437-46.
8. Rossi F, Rossi E, Pareti FI et al. In vitro measurement of platelet glycoprotein IIb/IIIa receptor blockade by abciximab: interindividual variation and increased platelet secretion. Haematologica 2001; 86: 192-8.
9. Quinn MJ, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa inhibitors: recognition of a two-edged sword? Circulation 2002; 106: 379-85.
10. Angiolillo DJ, Sabate M, Fernandez-Ortiz A et al. Aute stent thrombosis after early withdrawal of platelet glycoprotein IIb/IIIa antagonists: potential rebound prothrombotic effect? Catheter Cardiovasc Interv 2003; 58: 481-4.
11. Aguirre FV, Topol EJ, Ferguson JJ et al. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. EPIC Investigators. Circulation 1995; 91: 2882-90.
12. Weikert U, Kuhl U, Schultheiss HP,. Increased platelet activation in patients with cardoimyopathy: Myocardial inflammation and platelet reactivity. Platelets 2002; 13: 487-91.
13. Jaster M, Fuster V, Rosenthal P et al. Catheter based intracoronary brachytherapy leads to increased platelet activation. Heart 2004; 90: 160-4.
14. Jaster M, Schwimmbeck P, Spencker S et al. Randomized comparison of platelet-leukocyte aggregates and platelet activation in blood: heparin-coated coiled wire stent implantation versus balloon angioplasty in acute myocardial infarction. Thromb Res 2003; 112: 285-9.
15. Piorkowski M, Weikert U, Schwimmbeck PL et al. ADP induced platelet degranulation in healthy individuals is reduced by clopidogrel after pretreatment with atorvastatin. Thromb Haemost 2004; 92: 614-20.
16. Smith JW, Steinhuhl SR, Lincoff M, Rapid platelet function assay. An automated and quantitative cartridge-based method. Circulation 1999; 99: 620-5.
17. Osende JI, Fuster V, Lev EI, Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests. Relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. Circulation 2001; 103: 1488-91.
18. Steinhubl SR, Talley JD, Braden GA, Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention. Results of the GOLD (AU-assessing Ultegra) multicenter study. Circulation 2001; 103: 2572 8.
19. Nannizzi-Alaimo L, Alves VL, Phillips DR. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 2003; 107: 1123-8.
20. Cox D, Smith R, Quinn M et al. Evidence of platelet activation during treatment with a GPIIb/IIIa antagonist in patients presenting with acute coronary syndromes. J Am Coll Cardiol 2000; 36: 1514-9.
21. Holmes MB, Sobel BE, Cannon CP, Schneider DJ. Increased platelet reactivity in patients given orbofiban after an acute coronary syndrome: an OPUS-TIMI 16 substudy. Orbofiban in Patients with Unstable coronary syndromes. Thrombolysis In Myocardial Infarction. Am J Cardiol 2000; 85: 491-3, A10.
22. Collet JP, Montalescot G, Lesty C et al. Effects of Abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation. 2001; 103: 2328-31.
23. Goto S, Tamura N, Ishida H. Ability of anti-glycoprotein IIb/IIIa agents to dissolve platelet thrombi formed on a collagen surface under blood flow conditions. J Am Coll Cardiol 2004; 44: 316-23.
24. Ammar T, Scudder LE, Coller BS. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time. Circulation 1997; 95: 614-7.
25. Moliterno DJ, Califf RM, Aguirre FV et al. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications trial. Am J Cardiol 1995; 75: 559-62.
26. Ambrose JA, Hawkey M, Badimon JJ et al. In vivo demonstration of an antithrombin effect of abciximab. Am J Cardiol 2000; 86: 150-2.
27. Butenas S, Cawthern KM, van't Veer C et al. Lock JB, Mann KG. Antiplatelet agents in tissue factor-induced blood coagulation. Blood 2001; 97: 2314-22.
28. Reverter JC, Beguin S, Kessels H et al. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996; 98: 863-74.